Being a cell-surface tumor antigen, CSPG4 represents an ideal target for effective anti-cancer immunotherapy as CSPG4+ cancer cells are potentially susceptible to the concomitant attack of vaccine-inducible T cells and antibodies (20, 91). This evidence concerns the gene CSPG4 and cancer.